Overview on neurological manifestations of thyroid disease
Plaintiffs allege that drugmakers failed to properly warn patients and medical providers about these risks
(Since initial publication, one of these three companies, BSO LLC, which was making sterile pellets was inspected June 27th, 2025, and received a Form 483 in follow up.) Ultimately, the lack of inspections for registered 503B facilities puts patients at risk
However, persistent or severe infections may warrant temporary dose reduction or brief treatment pause
Its potential to modulate metabolic and neuroprotective pathways offers hope for the development of new therapies that could improve the prognosis of patients with both diseases
Clinical research confirms better IIEF scores with ongoing use of L-carnitine